Reforming Off-Label Promotion to Enhance Orphan Disease Treatment

被引：22

作者：

Liang, Bryan A. ^{[1
,2
]}

Mackey, Tim ^{[1
]}

机构：

[1] Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA 92101 USA

[2] Univ Calif San Diego, San Diego Sch Med, San Diego Ctr Patient Safety, Dept Anesthesiol, San Diego, CA 92103 USA

来源：

关键词：

DRUGS; FDA;

D O I：

10.1126/science.1181567

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

引用

页码：273 / 274

页数：2

共 22 条

[1]

ABELSON R, 2009, NY TIMES 0127, pA22, DOI DOI 10.1007/S00228-005-0981-Y

[2]

[Anonymous], 1996, Fed. RegOct. 8, V61, P52800

[3]

Berenson Alex, 2006, N Y Times Web, pC2

[4] Off label use-label off use? [J].

Boos, J .

Brewer, George J. .

[6]

Canadian Organization for Rare Disorders, 2005, CAN ORPH DRUG POL LE

[7]

*DHHS, 2001, OEI090000380 DHHS

[8]

FDA, 2009, GOOD REPR PRACT DIST

[9] Experts weigh in on promotion, prescription of off-label drugs [J].

Hampton, Tracy .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (07) :683-684

[10]

Krammer M, 2003, NATL ORG RARE DISORD